ADAM22

Across TCGA pan-cancer cohorts, ADAM22 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ADAM22 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADAM22 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADAM22 expression acts as an unfavorable survival marker.

PDAC and LSCC are the cancer types where ADAM22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.255	0.455	.012	18	view →
LSCC	DFS	Median	III,IV	0.230	0.952	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ADAM22–PDAC (DFS)

Open the PDAC breakdown →